Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Cancer Research

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Molecular Biology

Show all topics

DOI

10.1158/1078-0432.ccr-08-0596